Research New Upcoming Clinical Trials

We are excited to announce that the Medical Care and Research Services Department will be conducting the following clinical trials. Please feel free to contact the research program for more information.

Tobira 652-2-202 – A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each with Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naive, Adult Patients with only CCR5-Tropic Virus.

A4001095 – A Multicenter, Randomized, Double-Blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir for the treatment of Antiretrovirl-Naive HIV-Infected Patients with CCR5-Tropic HIV-1.

Research Currently Enrolling Trials

A4001098 – A Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the safety of Maraviroc in combination with other Antiretroviral agents in HIV-1 infected subjects co-infected with Hepatitis C and/or Hepatitis B Virus.

EPZ113734 – A Prospective, Randomized, Multicenter, Open-label Study to compare the efficacy and safety of simplifying from a regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine without Ritonafir for 48 weeks in Virologically suppressed, HIV-1 infected, HLAB* 5701 Negative Subjects.